SRPT

[COMPANY] Announces FDA Accelerated Approval of [DRUG] ([DRUG]) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51

[DATE] 1:40 PM EDT

[DRUG]—the first DMD treatment approved in the US—targets dystrophin deficiency, the underlying cause of Duchenne.

U.S. commercial launch planned to commence immediately.

Conference call scheduled for [DATE], 4:00 p.m. EST.
—[DATE]—[COMPANY], Inc. ([TICKER]: [TICKER]), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for [DRUG] ([DRUG]) as a once-weekly intravenous infusion of 30 milligrams per kilogram for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping. This indication is based on an increase in dystrophin in skeletal muscles observed in some patients treated with [DRUG]. A clinical benefit of [DRUG] has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. The most common adverse reactions compared to a placebo group were vomiting (38%) and balance disorder (38%), with contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection also reported more frequently than placebo (≥ 10%).

"Today's accelerated approval of [DRUG] represents a major milestone in the treatment of Duchenne Muscular Dystrophy for patients amenable to skipping exon 51 by targeting the underlying genetic cause of the disease – the lack of the dystrophin protein," said [EXECUTIVE], M.D., [COMPANY]'s interim chief executive officer and chief medical officer. "We are grateful to the many patients and investigators who participated in [DRUG]'s clinical studies. [DRUG] represents the culmination of many years of work across our entire organization and the Duchenne community to address a critical unmet need by bringing this novel medicine to patients. We will continue to leverage what we have learned from [DRUG] to facilitate future development of potential new treatments targeting additional exons with the goal of one day treating all DMD patients amenable to exon skipping."

The underlying cause of Duchenne muscular dystrophy is a mutation or error in the gene for dystrophin, an essential protein involved in muscle fiber function. Certain genetic mutations in DMD involve the deletion of exons, which interrupt proper translation of the genetic code into protein.

Duchenne muscular dystrophy is a fatal genetic neuromuscular disorder affecting an estimated one in approximately every 3,500–5,000 males born worldwide. It is estimated that up to thirteen percent of people with DMD have mutations addressable by [DRUG].

Patients and physicians can access information by calling 1-888-727-3782.

Conference Call
The Company will be hosting a conference call at 4:00 p.m. EST. The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 85217990. Please specify to the operator that you would like to join the "[COMPANY] Corporate Update." The conference call will be webcast live under the investor relations section of [COMPANY]'s website.